{"title":"多组区间有界纵向数据分布的复合半参数齐性检验。","authors":"Zhanfeng Wang, Wenmei Li, Hao Ding, Dongsheng Tu","doi":"10.1080/10543406.2023.2275769","DOIUrl":null,"url":null,"abstract":"<p><p>Motivated by comparing the distribution of longitudinal quality of life (QoL) data among different treatment groups from a cancer clinical trial, we propose a semiparametric test statistic for the homogeneity of the distributions of multigroup longitudinal measurements, which are bounded in a closed interval with excess observations taking the boundary values. Our procedure is based on a three-component mixed density ratio model and a composite empirical likelihood for the longitudinal data taking values inside the interval. A nonparametric bootstrap method is applied to calculate the p-value of the proposed test. Simulation studies are conducted to evaluate the proposed procedure, which show that the proposed test is effective in controlling type I errors and more powerful than the procedure which ignores the values on the boundaries. It is also robust to the model mispecification than the parametric test. The proposed procedure is also applied to compare the distributions of the scores of Physical Function subscale and Global Heath Status between the patients randomized to two treatment groups in a cancer clinical trial.</p>","PeriodicalId":54870,"journal":{"name":"Journal of Biopharmaceutical Statistics","volume":" ","pages":"58-69"},"PeriodicalIF":1.2000,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A composite semiparametric homogeneity test for the distributions of multigroup interval-bounded longitudinal data.\",\"authors\":\"Zhanfeng Wang, Wenmei Li, Hao Ding, Dongsheng Tu\",\"doi\":\"10.1080/10543406.2023.2275769\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Motivated by comparing the distribution of longitudinal quality of life (QoL) data among different treatment groups from a cancer clinical trial, we propose a semiparametric test statistic for the homogeneity of the distributions of multigroup longitudinal measurements, which are bounded in a closed interval with excess observations taking the boundary values. Our procedure is based on a three-component mixed density ratio model and a composite empirical likelihood for the longitudinal data taking values inside the interval. A nonparametric bootstrap method is applied to calculate the p-value of the proposed test. Simulation studies are conducted to evaluate the proposed procedure, which show that the proposed test is effective in controlling type I errors and more powerful than the procedure which ignores the values on the boundaries. It is also robust to the model mispecification than the parametric test. The proposed procedure is also applied to compare the distributions of the scores of Physical Function subscale and Global Heath Status between the patients randomized to two treatment groups in a cancer clinical trial.</p>\",\"PeriodicalId\":54870,\"journal\":{\"name\":\"Journal of Biopharmaceutical Statistics\",\"volume\":\" \",\"pages\":\"58-69\"},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2025-01-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Biopharmaceutical Statistics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/10543406.2023.2275769\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/11/15 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Biopharmaceutical Statistics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10543406.2023.2275769","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/15 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
A composite semiparametric homogeneity test for the distributions of multigroup interval-bounded longitudinal data.
Motivated by comparing the distribution of longitudinal quality of life (QoL) data among different treatment groups from a cancer clinical trial, we propose a semiparametric test statistic for the homogeneity of the distributions of multigroup longitudinal measurements, which are bounded in a closed interval with excess observations taking the boundary values. Our procedure is based on a three-component mixed density ratio model and a composite empirical likelihood for the longitudinal data taking values inside the interval. A nonparametric bootstrap method is applied to calculate the p-value of the proposed test. Simulation studies are conducted to evaluate the proposed procedure, which show that the proposed test is effective in controlling type I errors and more powerful than the procedure which ignores the values on the boundaries. It is also robust to the model mispecification than the parametric test. The proposed procedure is also applied to compare the distributions of the scores of Physical Function subscale and Global Heath Status between the patients randomized to two treatment groups in a cancer clinical trial.
期刊介绍:
The Journal of Biopharmaceutical Statistics, a rapid publication journal, discusses quality applications of statistics in biopharmaceutical research and development. Now publishing six times per year, it includes expositions of statistical methodology with immediate applicability to biopharmaceutical research in the form of full-length and short manuscripts, review articles, selected/invited conference papers, short articles, and letters to the editor. Addressing timely and provocative topics important to the biostatistical profession, the journal covers:
Drug, device, and biological research and development;
Drug screening and drug design;
Assessment of pharmacological activity;
Pharmaceutical formulation and scale-up;
Preclinical safety assessment;
Bioavailability, bioequivalence, and pharmacokinetics;
Phase, I, II, and III clinical development including complex innovative designs;
Premarket approval assessment of clinical safety;
Postmarketing surveillance;
Big data and artificial intelligence and applications.